Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganwu nasal live attenuated influenza vaccine in children and adolescents
CTR20232853Phase 4Completed
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in influenza comparing Ganwu with Placebo (2 arms). Primary endpoints: Protective efficacy against laboratory-confirmed influenza 14 days after vaccination and Protective efficacy against laboratory-confirmed influenza by serotype 14 days after vaccination. Started Sep 2023; status: completed.
02
Drugs
Ganwu
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20232853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232853.